Anticancer drugs: where are we now?

References

• Jassim A, Rahrmann EP, Simons BD, et al. Cancers make their own luck: theories of cancer origins. Nat Rev Cancer. 2023;23(10):710–724. doi: 10.1038/s41568-023-00602-5
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi: 10.1016/j.cmet.2015.12.006
   PubMed Web of Science ®Google Scholar
• Chiarugi A, Dölle C, Felici R, et al. The NAD metabolome–a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741–752. doi: 10.1038/nrc3340
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10(10):767–777. doi: 10.1038/nrd3554
   PubMed Web of Science ®Google Scholar
• Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17(2):164–170. doi: 10.2174/1871520616666161031143301
   PubMed Web of Science ®Google Scholar
• Mullard A. The high, and redundant, cost of failure in cancer drug development. Nat Rev Drug Discov. 2023;22(9):688. doi: 10.1038/d41573-023-00132-7
   PubMed Web of Science ®Google Scholar
• Peerzada MN, Hamel E, Bai R, et al. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacol Ther. 2021;225:107860. doi: 10.1016/j.pharmthera.2021.107860
   PubMed Web of Science ®Google Scholar
• Tao R, Han X, Bai X, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024;15:1354825. doi: 10.3389/fimmu.2024.1354825
   PubMed Web of Science ®Google Scholar
• Supuran CT. Targeting carbonic anhydrases for the management of hypoxic metastatic tumors. Expert Opin Ther Pat. 2023;33(11):701–720. doi: 10.1080/13543776.2023.2245971
   PubMed Web of Science ®Google Scholar
• Melfi F, Carradori S, Mencarelli N, et al. Natural products as a source of new anticancer chemotypes. Expert Opin Ther Pat. 2023;33(11):721–744. doi: 10.1080/13543776.2023.2265561
   PubMed Web of Science ®Google Scholar
• Romano F, Di Porzio A, Iaccarino N, et al. G-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting. Expert Opin Ther Pat. 2023;33(11):745–773. doi: 10.1080/13543776.2023.2271168
   PubMed Web of Science ®Google Scholar
• Gazzaroli G, Angeli A, Giacomini A, et al. Proteasome inhibitors as anticancer agents. Expert Opin Ther Pat. 2023;33(11):775–796. doi: 10.1080/13543776.2023.2272648
   PubMed Web of Science ®Google Scholar
• Peerzada MN, Dar MS, Verma S. Development of tubulin polymerization inhibitors as anticancer agents. Expert Opin Ther Pat. 2023;33(11):797–820. doi: 10.1080/13543776.2023.2291390
   PubMed Web of Science ®Google Scholar
• Gioiello A, Rosatelli E, Cerra B. Patented farnesoid X receptor modulators: a review (2019 – present). Expert Opin Ther Pat. 2024 Feb;26:1–18. doi: 10.1080/13543776.2024.2314296
   Google Scholar
• Viviano M, Cipriano A, Fabbrizi E, et al. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review. Expert Opin Ther Pat. 2024 Mar;11:1–17. doi: 10.1080/13543776.2024.2327300
   Google Scholar
• Carta F, et al. Kinase inhibitors: 20 years of success and many new challenges. Expert Opin Ther Pat. 2024; in press.
   Google Scholar
• Gasparrini M, Giovannuzzi S, Nocentini A, Raffaelli N, Supuran CT. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review. Expert Opin Ther Pat. 2024; in press.
   Google Scholar
• Nerella SG, Singh P, Arifuddin M, et al. Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018–2022. Expert Opin Ther Pat. 2022;32(8):833–847. doi: 10.1080/13543776.2022.2083502
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2021;30(12):1197–1208. doi: 10.1080/13543784.2021.2014813
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chafe SC, Supuran CT, et al. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers (Basel). 2022;14(14):3297. doi: 10.3390/cancers14143297
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10(10):412. doi: 10.3390/metabo10100412
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase versatility: from pH regulation to CO2 sensing and metabolism. Front Mol Biosci. 2023;10:1326633. doi: 10.3389/fmolb.2023.1326633
   PubMed Web of Science ®Google Scholar
• Chafe SC, Vizeacoumar FS, Venkateswaran G, et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv. 2021;7(35):eabj0364. doi: 10.1126/sciadv.abj0364
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol. 2020;43(7):484–490. doi: 10.1097/COC.0000000000000691
   PubMed Web of Science ®Google Scholar
• Atanasov AG, Zotchev SB, Dirsch VM. International natural product sciences taskforce; supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–216. doi: 10.1038/s41573-020-00114-z
   PubMed Web of Science ®Google Scholar
• Clark GR, Pytel PD, Squire CJ, et al. Structure of the first parallel DNA quadruplex-drug complex. J Am Chem Soc. 2003;125(14):4066–4067. doi: 10.1021/ja0297988
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Chen S, Roman-Escorza M, et al. Structure-activity relationships for the G-quadruplex-targeting experimental drug QN-302 and two analogues probed with comparative transcriptome profiling and molecular modeling. Sci Rep. 2024;14(1):3447. doi: 10.1038/s41598-024-54080-2
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 2014;53(16):4231–4235. doi: 10.1002/anie.201310709
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Pruzanski M, Gioiello A. The discovery of obeticholic acid (Ocaliva™): first-in-class FXR agonist. In: Fischer J, Klein C Childers W, editors. Successful drug discovery. Vol. 3. Wiley-VCH Verlag GmbH & Co. KGaA; 2018. p. 197–244. doi: 10.1002/9783527808694.ch8
   Google Scholar